Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26361552 | 0.81 | CYP1A2 (0.48) | SCN5ACYP1A2MAOAMAOBDYRK1A | |
| SCHEMBL20190305 | 0.80 | SCN5A (0.68) | SCN5ACYP1A2MAOAMAOBABL1 | |
| SCHEMBL20190452 | 0.78 | SCN5A (0.55) | SCN5ACYP1A2MAOAMAOBGPR3 | |
| SCHEMBL22712306 | 0.78 | CYP1A2 (0.50) | SCN5ACYP1A2MAOAMAOBDYRK1A | |
| SCHEMBL20190530 | 0.77 | CYP1A2 (0.45) | SCN5ACYP1A2MAOAMAOBDYRK1A | |
| SCHEMBL20190211 | 0.77 | CYP1A2 (0.47) | SCN5ACYP1A2MAOAMAOBDYRK1A | |
| SCHEMBL20189738 | 0.77 | SCN5A (0.65) | SCN5ACYP1A2MAOAMAOBDYRK1A | |
| SCHEMBL20190430 | 0.75 | CYP1A2 (0.43) | SCN5ACYP1A2MAOAMAOBDYRK1A | |
| SCHEMBL26361527 | 0.74 | SCN5A (0.50) | SCN5ACYP1A2MAOAMAOBGPR3 | |
| SCHEMBL20191130 | 0.73 | SCN5A (0.47) | SCN5ACYP1A2MAOAMAOBGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885MAOA 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.